Cardiff Oncology, Inc. (CRDF) vs VAXART, INC. (VXRT)

Cardiff Oncology, Inc. and VAXART, INC. are both Biotechnology companies. Cardiff Oncology, Inc. and VAXART, INC. are of similar size ($99.6M and $92.4M). Cardiff Oncology, Inc. has negative trailing earnings, so its P/E is not meaningful; VAXART, INC. trades at 2.8×. VAXART, INC. grew revenue faster over the last twelve months: 201.1% against −6.79%. VAXART, INC. has the higher net margin (15.9% vs −7,889.0%) and the higher return on invested capital (134.6% vs 0.00%). Across the 16 metrics below, VAXART, INC. leads on 15 and Cardiff Oncology, Inc. on 1.

Valuation

Metric CRDF VXRT Biotechnology median
P/E n/m 2.81 7.88
P/S 166.95 0.45 11.47
P/B 3.20 1.32 2.52
Price to free cash flow n/m 3.26 21.16
EV/EBITDA n/m 1.49 0.74
EV/Sales 103.52 0.28 10.73
Earnings yield (48.39%) 35.56% (28.84%)
Free cash flow yield (48.27%) 30.65% (23.03%)

Profitability

Metric CRDF VXRT Biotechnology median
Gross margin 100.00% 100.00% 65.16%
Operating margin (8,320.08%) 16.30% 0.00%
Net margin (7,888.98%) 15.88% 0.00%
Free cash flow margin (8,059.45%) 13.74% 0.00%
Return on equity (94.14%) 66.97% (57.72%)
Return on assets (70.89%) 23.44% (49.22%)
Return on invested capital 0.00% 134.59% 0.00%

Growth

Metric CRDF VXRT Biotechnology median
Revenue growth (TTM) (6.79%) 201.10% 5.64%
EPS growth (last fiscal year) 27.37% 121.21% —
Revenue growth, 5-year CAGR 10.13% 125.76% 8.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric CRDF VXRT Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 3.30 1.60 4.73
Net debt to EBITDA 1.18 (2.42) 0.96

Dividend

Metric CRDF VXRT Biotechnology median
Dividend yield — 3.63% 2.10%
Payout ratio 0.00 0.00 0.00

Size

Metric CRDF VXRT Biotechnology median
Market cap 99.58m 92.41m 162.10m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack